Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys

Molecular Therapy

Volumn 20, Issue 5, 2012, Pages 1033-1045

  Tarantal, Alice F ^a,b   Giannoni, Francesca ^c   I Lee, C Chang ^a,b   Wherley, Jennifer ^c   Sumiyoshi, Teiko ^c   Martinez, Michele ^a,b   Kahl, Christoph A ^c,f   Elashoff, David ^d   Louie, Stan G ^e   Kohn, Donald B ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD34 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; FLUDARABINE; LENTIVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA MODIFICATION; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; ENGRAFTMENT; ENHANCED GREEN FLUORESCENT PROTEIN GENE; GENE; GENE DOSAGE; GENETIC TRANSDUCTION; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL; HUMORAL IMMUNITY; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; NONEXPRESSED NEOMYCIN TRANSFERASE GENE; NONHUMAN; NONMYELOABLATIVE CONDITIONING; REPORTER GENE; RHESUS MONKEY; SINGLE DRUG DOSE; STEM CELL GENE THERAPY; STOP CODON; THROMBOCYTOPENIA;

MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84860542947     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.312     Document Type: Article

References (40)

1. Bordignon, C, Notarangelo, LD, Nobili, N, Ferrari, G, Casorati, G, Panina, P et al. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270: 470-475.
2. Kohn, DB, Weinberg, KI, Nolta, JA, Heiss, LN, Lenarsky, C, Crooks, GM et al. (1995). Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1: 1017-1023.
3. Malech, HL, Maples, PB, Whiting-Theobald, N, Linton, GF, Sekhsaria, S, Vowells, SJ et al. (1997). Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 94: 12133-12138. (Pubitemid 27467855)
4. Hacein-Bey-Abina, S, Le Deist, F, Carlier, F, Bouneaud, C, Hue, C, De Villartay, JP et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193. (Pubitemid 34984579)
5. Gaspar, HB, Parsley, KL, Howe, S, King, D, Gilmour, KC, Sinclair, J et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187. (Pubitemid 40018447)
6. Hacein-Bey-Abina, S, Hauer, J, Lim, A, Picard, C, Wang, GP, Berry, CC et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363: 355-364.
7. Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413. (Pubitemid 34734219)
8. Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360: 447-458.
9. Riddell, SR, Elliott, M, Lewinsohn, DA, Gilbert, MJ, Wilson, L, Manley, SA et al. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2: 216-223. (Pubitemid 26057556)
10. Tuschong, L, Soenen, SL, Blaese, RM, Candotti, F and Muul, LM (2002). Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther 13: 1605-1610. (Pubitemid 35034680)
11. Kahl, CA, Tarantal, AF, Lee, CI, Jimenez, DF, Choi, C, Pepper, K et al. (2006). Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp Hematol 34: 369-381.
12. Stripecke, R, Carmen Villacres, M, Skelton, D, Satake, N, Halene, S and Kohn, D (1999). Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 6: 1305-1312. (Pubitemid 29359025)
13. Skelton, D, Satake, N and Kohn, DB (2001). The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. Gene Ther 8: 1813-1814. (Pubitemid 34100583)
14. Andersson, G, Illigens, BM, Johnson, KW, Calderhead, D, LeGuern, C, Benichou, G et al. (2003). Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood 101: 4305-4312. (Pubitemid 36857794)
15. Rosenzweig, M, Connole, M, Glickman, R, Yue, SP, Noren, B, DeMaria, M et al. (2001). Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 97: 1951-1959. (Pubitemid 32239073)
16. Berger, C, Huang, ML, Gough, M, Greenberg, PD, Riddell, SR and Kiem, HP (2001). Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of genemodified autologous T cells in a nonhuman primate model. J Virol 75: 799-808. (Pubitemid 32037283)
17. Morris, JC, Conerly, M, Thomasson, B, Storek, J, Riddell, SR and Kiem, HP (2004). Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood 103: 492-499. (Pubitemid 38140079)
18. Donahue, RE, Wersto, RP, Allay, JA, Agricola, BA, Metzger, ME, Nienhuis, AW et al. (2000). High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34(+) cells. Blood 95: 445-452. (Pubitemid 30041655)
19. Hutton, JJ, Von Hoff, DD, Kuhn, J, Phillips, J, Hersh, M and Clark, G (1984). Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2- fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 44: 4183-4186. (Pubitemid 14041655)
20. Von Hoff, DD (1990). Phase I clinical trials with fludarabine phosphate. Semin Oncol 17(5 Suppl 8): 33-38. (Pubitemid 20356426)
21. Goodman, ER, Fiedor, PS, Fein, S, Athan, E and Hardy, MA (1996). Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am Surg 62: 435-442. (Pubitemid 26158143)
22. Bonin, M, Pursche, S, Bergeman, T, Leopold, T, Illmer, T, Ehninger, G et al. (2007). F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone Marrow Transplant 39: 201-206.
23. Von Hoff, DD (1990). Phase I clinical trials with fludarabine phosphate. Semin Oncol 17: 33-38. (Pubitemid 20356426)
24. Avramis, VI, Champagne, J, Sato, J, Krailo, M, Ettinger, LJ, Poplack, DG et al. (1990). Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 50: 7226-7231.
25. Wu, T, Kim, HJ, Sellers, SE, Meade, KE, Agricola, BA, Metzger, ME et al. (2000). Prolonged high-level detection of retrovirally marked hematopoietic cells in nonhuman primates after transduction of CD34+ progenitors using clinically feasible methods. Mol Ther 1: 285-293.
26. Kiem, HP, Andrews, RG, Morris, J, Peterson, L, Heyward, S, Allen, JM et al. (1998). Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood 92: 1878-1886. (Pubitemid 28446676)
27. Shaw, KL, Sokolic, R and Choi, C (2009). Immune reconstitution after gene therapy for adenosine deaminase deficient severe combined immune deficiency (ADA-SCID). Mol Ther 17: S138.
28. Hale, G, Hoang, T, Prospero, T, Watt, SM and Waldmann, H (1983). Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med 1: 305-319.
29. Long-Boyle, JR, Green, KG, Brunstein, CG, Cao, Q, Rogosheske, J, Weisdorf, DJ et al. (2011). High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant 46: 20-26.
30. Kim, YJ, Kim, YS, Larochelle, A, Renaud, G, Wolfsberg, TG, Adler, R et al. (2009). Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells. Blood 113: 5434-5443.
31. An, DS, Kung, SK, Bonifacino, A, Wersto, RP, Metzger, ME, Agricola, BA et al. (2001). Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. J Virol 75: 3547-3555. (Pubitemid 32246364)
32. Trobridge, GD, Beard, BC, Gooch, C, Wohlfahrt, M, Olsen, P, Fletcher, J et al. (2008). Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors. Blood 111: 5537-5543.
33. Hanawa, H, Hematti, P, Keyvanfar, K, Metzger, ME, Krouse, A, Donahue, RE et al. (2004). Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 103: 4062-4069. (Pubitemid 38685345)
34. Hanazono, Y, Brown, KE, Handa, A, Metzger, ME, Heim, D, Kurtzman, GJ et al. (1999). In vivo marking of rhesus monkey lymphocytes by adeno-associated viral vectors: direct comparison with retroviral vectors. Blood 94: 2263-2270. (Pubitemid 29467674)
35. Shaw, KL, Pais, E, Ge, S, Hardee, C, Skelton, D, Hollis, RP et al. (2009). Lentiviral vectors with amplified beta cell-specific gene expression. Gene Ther 16: 998-1008.
36. Tarantal, AF (2005). Ultrasound Imaging in Rhesus and Long-tailed Macaques: Reproductive and Research Applications. In: Woolf-Coote, S (ed). The Laboratory Primate. Elsevier Academic Press, pp 317-351.
37. Tarantal, AF, McDonald, RJ, Jimenez, DF, Lee, CC, O'Shea, CE, Leapley, AC et al. (2005). Intrapulmonary and intramyocardial gene transfer in rhesus monkeys (Macaca mulatta): safety and efficiency of HIV-1-derived lentiviral vectors for fetal gene delivery. Mol Ther 12: 87-98. (Pubitemid 40862360)
38. Tarantal, AF, Goldstein, O, Barley, F and Cowan, MJ (2000). Transplantation of human peripheral blood stem cells into fetal rhesus monkeys (Macaca mulatta). Transplantation 69: 1818-1823. (Pubitemid 30340340)
39. DuBois, D and DuBois E (1916). A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17: 863-871.
40. Lee, CC, Fletcher, MD and Tarantal, AF (2005). Effect of age on the frequency, cell cycle, and lineage maturation of rhesus monkey (Macaca mulatta) CD34+ and hematopoietic progenitor cells. Pediatr Res 58: 315-322. (Pubitemid 41099880)